Posts

7 days in healthcare (April 17th-23rd, 2023)

 

Summary

From the point of view of Biomedicine, this week, exceptionally, two important advances in Spain are mentioned. On the one hand, the important investigations of the team led by Dr. Obeso, at HM Hospitales, on how to “open” the blood-brain barrier, that barrier that, among other things, prevented the arrival of drugs to the brain. It seems that in this way possibilities could be opened for the treatment of Parkinson’s. On the other hand, at the Vall d’Hebrón Hospital in Barcelona, the first robotic lung transplant was approached through a small incision.

As far as Global Health is concerned, there is a great alarm, highlighted by UNICEF and The Lancet magazine, about the drop in immunizations in children after the covid. Although the covid highlighted the efficacy of the vaccines, it brought the side effect of this drop in immunizations globally. In Uganda, the new anti-homosexuality law takes repression against this sexual option to an extreme, endangering anti-HIV campaigns in that country. The G7, to be held in Japan in May, emphasizes various health issues, including the importance of universal health coverage and the need for resilient health systems.

Regarding International Health Policy, the WHO warns of the non-solution of the covid problem, since in the last 28 days there were 23,000 deaths and 3 million new cases globally, even with reduced test figures. High mortality in the USA, with around 245 deaths per day. In the United States, the government is preparing to finalize the guidelines for negotiating the price of drugs in Medicare in July, something totally new in that country and that is shocking the pharmaceutical industry. The American Supreme Court rectifies its previous decisions and allows the abortion pill mifepristone to continue to be used, amid abundant criticism of the Court, for having questioned something that the FDA had already authorized more than 20 years ago. According to The Economist, the annulment of the Roe v Wade ruling caused the number of abortions in the USA to drop by 6%. In the United Kingdom, the consequences in the NHS of the multiple and continuous strikes and conflicts of health personnel continue. The German government is clashing with other European governments in its efforts to reduce the timeframe for generics to appear, calling into question the pharmaceutical investment model, according to some.

If we talk about National Health Policy (Spain), the incidence of covid continues to rise, amid controversies about the advisability or not of suppressing masks where they are still mandatory (health centers, social health centers and pharmacies). Conflicts with health personnel continue in several autonomous communities. In public healthcare, quite important allocation of resources by the Ministry to primary care and mental health. In private health, in the first quarter of the year there was a growth of 7.5% in the policies of private health insurers. “Voting with your feet” is called that figure. The IDIS Foundation focuses, through an interesting publication, on an important problem: the mental health situation in our country. Since we have few problems, Catalonia insists on an artificial conflict: the use of Catalan in the healthcare system in that autonomous community. Both in Aragon and in Castilla-La Mancha, two initiatives of dubious utility and even suspected of electoralism are launched. In Aragon, a national debate on health is proposed through a very typical document of those that come out in the autonomous communities that could be summarized as “More money for health without reforms.” As for Castilla-La Mancha, a law on waiting lists is promoted, when the terminal state of the legislature suggests that it will not be approved.

In the field of Companies, internationally, Nestlé is accused of manufacturing unhealthy products, due to their high load of fat, sugar and salt. Merck makes a major investment buying Prometheus Biosciences for $11 billion. At the national level, Moderna opens a laboratory in Madrid.

Biomedicine

Global Health

International Health Policy

National health policy

Companies

7 days in healthcare (October, 3rd-9th, 2022)

 

Summary

From the point of view of biomedicine, to review the Nobel Prize in Physiology and Medicine, won by Svante Pääbo, a scientist who is recognized for his studies on the DNA of human ancestors, which allows us to better understand genetic evolution towards the “homo sapiens”. It seems that a study with Artificial Intelligence of the eye will help predict coronary risk in minutes, without the need for blood tests or other studies.

As far as Global Health is concerned, it is believed that malaria could be definitively eradicated from the world, with the help of new vaccines.

As for international health policy, alerts in Europe about avian flu and diphtheria, brought by immigrants from Africa and Asia. To highlight the changes in Portugal, which incorporate an independent team to the management of the SNS.

If we talk about national health policy (Spain), the rise in covid cases prevents the Interterritorial Council from approving the abolition of masks on public transport. The health items in the General State Budgets are analyzed with a magnifying glass in the professional press, despite the low weight of the expenses of the Central Administration in the total health expenses. However, it allows to detect some priorities for the Ministry, although the economic items are usually below the challenges: primary care, genomic portfolio, mental health, dental care, primary care infrastructure, etc. The CEOE charges against the Equity Law, which it describes as “unprecedented risk”. The debates and controversies continue in relation to the delays in the incorporation of pharmaceutical innovation in Spain. However, these debates do not usually consider that the approval by the EMA of a medicine does not mean automatic public financing in Spain, according to article 92 of the Law on Guarantees and rational use of medicines, which establishes the “financing selective and not indiscriminate” according to a series of criteria, which are established. AESEG and BIOSIM no longer agree with the plan approved a couple of years ago on generics and biosimilars, but want the new approaches to be included in the Guarantees Law.

In the field of companies, in the international arena, BioNTech signs an agreement with Australia, for the establishment of research centers in that country. As for national news, the growing weight of online pharmacy (prescription drugs excluded by law). HM reinforces itself in Andalusia, incorporating four hospitals in Malaga into its network.

Biomedicine

Global Health

International health policy

National health policy

  • General State Budgets (impact on health)

Companies

 

7 days in healthcare (August 8th-14th, 2022)

 

Summary

From the point of view of biomedicine, there seems to be a glimpse of a new drug to prevent the transmission of HIV/AIDS, for which there are problems in obtaining an affordable price. Animal testing is the basis for certain advances in medicine. This can be overcome with certain new discoveries, according to the company Lift Sciences.

Regarding Global Health, two key issues: a new zoonosis (“Langya”) appears in China, as published in the NEJM. In certain developed countries it seems that polio, which was considered eradicated, is making a comeback.

Regarding international health policy, the approval of the Inflation Reduction Act (IRA) of 2022 in the United States, about Climate, Fiscal and Health will have a very important impact. Aside from expanding access to insurance through the Affordable Care Act (Obamacare), surely the most far-reaching impact will be on the pharmaceutical industry. Gradually, Medicare will be able to negotiate the price of medicines with the pharmaceutical industry, something that until now it could not do. This radically changes the business model of the pharmaceutical industry, which was based on two things: the protection of intellectual property through patents; and the existence of free prices with high margins in the United States (the largest pharmaceutical market) and regulated prices and lower margins in the rest of the world. A substantial change that will most likely have a global impact. It may also curb the escalation of health care spending in the United States. We’ll see if this doesn’t upset the fast pace of drug innovation.

If we talk about national health policy (Spain), the good news is that, as in all of Europe, covid continues to decrease in incidence, although it is still a worrying disease, due to the number of hospitalized cases and mortality.

In the field of companies, trials for new covid variants begin by BioNTech and Pfizer. More than 2,300 Spanish pharmacies can now sell through the Glovo platform and soon Uber, although only parapharmacy products, not prescription drugs.

Biomedicine

Global health

International health policy

National health policy

Companies

 

 

 

 

 

7 days in healthcare (January 24-30, 2022)

 

Summary

From the point of view of biomedicine, the concern regarding resistance to antibiotics continues, after the extensive report published by The Lancet. This pandemic produces more deaths than AIDS and malaria. New variant of “ómicron” appeared in Denmark.

With regard to global health, the tenth anniversary of the declaration on “Neglected tropical diseases” should be highlighted, which provides an opportunity to reflect on a change in which progress has been made, but much remains to be done. COVAX does not have the capacity to receive more donations in the absence of basic financing for the purchase of syringes and other materials, essential to administer the vaccine.

As for international news, the WHO will publish a plan for the transition of the pandemic to the “control phase” in February. IHI initiative, of the European Union, to create a public/private platform for drug research.

In national news from Spain, the sixth wave seems to be starting to subside in terms of new cases, but still with high mortality. Interesting report promoted by Vitaldent on the public financing of dental care. Biosim highlights the savings potential of biosimilars in 2022. The issue of professional recertification advances, with a leading role for FACME.

In company news, the approval by the EMA of Paxlovid, Pfizer’s antiviral pill against COVID, is important. Also the large expected growth in turnover by COVID vaccine manufacturers in 2022 (29%, compared to 2021). Boom of online psychology platforms

Biomedicine

  • It is time to confront the pandemic of antibiotic resistance, since this resistance causes more deaths than AIDS and malaria. AMR Action Fund, a public/private initiative to develop new antibiotics, is underway (FT, January 28, 22)
  • The new BA.2 omicron, which appeared in Denmark, the stealthy variant of the “‘omicron”, warns the WHO that it may not be detectable with PCR (La Razón, January 25, 22)
  • New research identifies the 4 factors that can favor prolonged covid (NYT, January 25, 22)

Global health

  • 10th anniversary of the London declaration on “Neglected tropical diseases”, much progress has been made. Trachoma, schistosomiasis and visceral leishmaniasis are the most frequent of this type of disease (The Lancet, January 29, 22)
  • Developed countries throw away 61.5 million vaccines for having expired in 2021 (El Español, January 28, 22)
  • World Day against Leprosy, the covid pandemic has silenced it, a disease almost eradicated in Europe but still present in the world (ConSalud, January 30, 22)
  • Lack of funding to buy syringes and other accessories means COVAX cannot accept new doses of vaccines (FT, 25 Jan 22)
  • The United States donated 400 million doses of covid vaccine to 112 countries, according to the White House (The Guardian, January 26, 22)
  • Project Syndicate magazine publishes an analysis (How Much Has the Pandemic Cost?) of the economic impact of the pandemic, based on years of life lost and the value of life in different countries. If the official figure of 5.6 million dead at the end of 2021 is taken, this means 38 trillion (American) dollars or 40% of global GDP; If the estimate of deaths from The Economist (17 million) is taken, we would reach 114 trillion or 120% of global GDP (Project Syndicate, January 27, 22)

International News

  • The WHO will publish in February a plan for the transition of the pandemic to the “control phase” (La Razón, January 24, 22)
  • Notable increase in telemedicine in Medicare (USA) during the pandemic (JAMA, January 25, 22)
  • The British Medical Association recommends the use of FPP3 mask to health professionals who have to deal with patients with viral respiratory disease (BMJ, 21 January 22)
  • The new normal in New Zealand goes from covid 0 to covid acceptance (The Guardian, 26 January 22)
  • An Israeli panel recommends the fourth dose to all adults (FT 25 Jan 22)
  • In Canada, demonstrations against compulsory vaccination (The Guardian, January 30, 22)
  • The European Union launches IHI, a public/private initiative for drug research, as a continuation of the Innovative Medicines Initiative, which was launched in 2008 (Acta Sanitaria, January 26, 22)

National News

  • COVID

o The epidemic curve in Spain consolidates its decline, but experts call for caution (El País, January 29, 22)

o The sixth wave already registers 5,674 deaths from covid and could exceed the sixth before February (El Español, January 27, 22)

o Health and the communities extend the limited capacity at sporting events (El País, January 26, 22)

o The anti-vaccines are responsible for increasing deaths by 32% in the sixth wave, according to Fedea (El Español, January 24, 22)

o Those vaccinated have a hundred times less chance of dying if they become infected (El Mundo, January 28, 22)

o Catalonia abolishes the covid passport (La Razón, January 26, 22)

  • Other issues

o Financing dental health (one of the promises of the PSOE-Unidos Podemos government program) will cost the State 5,423 million euros, according to a study promoted by Vitaldent and presented to the Ministry of Health (El Economista, January 25, 22)

o A third of doctors will retire in the next five years (The Objective, January 28, 22)

o Telemedicine is good for reducing CO2 into the atmosphere, it would reduce 277,120 tons of CO2 in Spain in Primary Care alone, according to the report prepared by “GEN Europe Energy Solutions” (ConSalud, January 28, 22)

o More than 13,000 applicants opt for the 8,200 MIR places in the exam on January 29 (Acta Sanitaria, January 28, 22)

o Biosim puts the savings on biosimilars at 1,048 million euros in 2022 (diariofarma, January 26, 22)

o FACME claims its role in the recertification and creates a specific council, chaired by Cecilio Santander (Diario Médico, January 28, 22)

o ISFAS statement on difficulties in negotiating insurance companies-hospital groups for the coverage of this group (Sanifax, January 24, 22)

Companies, employers and other agents of the sector

  • The EMA approves Paxlovid, Pfizer’s antiviral pill against covid (El Economista, January 27, 22)
  • The large vaccine manufacturers will invoice 75,000 million euros for the covid vaccine this year 2022, this is a 29% jump over the estimate for 2021, according to the consulting firm Airfinity (CincoDías, January 25, 22)
  • Pfizer will produce 120 million doses of its drug against covid in Europe (El Español, January 29, 22)
  • Cinfa leads the market in pharmacies and Novartis in hospitals (CincoDías, January 24, 22)
  • The French group Orpea with problems in its listing due to accusations of mistreatment (FT, January 27, 22)
  • BioNTech begins clinical trial for “ómicron” vaccine (FT, January 25, 22)
  • The business of mental health: boom in online psychology platforms (El Periódico de España, 30 January 22)
  • Mifarma (the leading company in Europe for the online sale of pharmacy and parapharmacy products) reinforces its position in Spain with a new image and online platform (La Razón, January 25, 22)
  • United Imaging Healthcare lands in Spain hand in hand with APR Salud (PlantaDoce, January 25, 22)
  • Sanitas is interested in the purchase of the IMQ (Redacción Médica, January 26, 22)
  • Healthcare Activos continues its expansion and will buy a residence in Ferrol (PlantaDoce, January 21, 22)
  • Corachán becomes stronger in Barcelona with a new center in Sarriá (PlantaDoce, 27 January 22)

7 days in healthcare (January 10-16, 2022)

 

SUMMARY

From the international point of view, several issues stand out. In the first place, the agreement of the French Assembly taken on Sunday, January 16, to prevent the access of the unvaccinated to leisure and restaurant premises; also Quebec’s initiative to introduce special taxes on the unvaccinated; the WHO’s opinion that it is too early for COVID “flu” policies, as proposed by Spain; the calculation by ISGlobal (Barcelona) that COVID has already left 17 million deaths globally; and the big push for research on neurodegenerative diseases.

As for national news, the SEMFYC (one of the Primary Care medical societies) editorial had a great impact defending the “flu” policies of COVID and, therefore, the minimization of measures, encouraging, consciously or unconsciously, the “light” negationism. This position was quickly adopted by the central government and certain authorities of the Community of Madrid. The central government even tried to lead this position at the international level. Rejection of this idea by other Primary Care societies, a large number of experts, the WHO and the EU. Meanwhile, the incidence of COVID continues to rise to figures never seen in other waves (2,923 cases per 100,000 inhabitants). The price of antigen tests is regulated, after multiple requests from various groups. It is agreed to extend the third and fourth doses. Serious problems regarding sick leave, for which solutions are articulated about the legality of which is in doubt. The purchase of COVID medicines is announced. Ayuso Plan to stimulate the birth rate in Madrid.

As far as companies and other actors are concerned, a group of scientists in Texas announce a vaccine against COVID, which, according to them, it will be cheaper, easier to make and patent-free. Pfizer announces that it will have a new vaccine against the “ómicron” variant ready in March

INTERNATIONAL NEWS

  • France: the Assembly approves by 215 votes against 58 the law that prevents the access of the unvaccinated to leisure and restaurant venues (Le Monde, Jan 16, 22)
  • Quebec’s plan on special taxes on the unvaccinated is well received in Europe. the argument is: “10% of the population cannot overload 90%”. Cold reception at the federal level in Canada and in other provinces. However, in Europe it is not receiving a bad reception: Greece and Austria already fine the unvaccinated, Italy is studying it, France extends the “covid passport” (BMJ, Jan 14, 22)
  • Fourth dose in Israel, which had already been announced for the immunosuppressed, is now being extended to health professionals and those over 60 years of age (Lancet Respir Med, Jan 11, 22)
  • The WHO considers that it is too early to treat COVID-19 as endemic, contradicting the Spanish government’s proposal, and predicts that half of Europeans can be infected (FT, Jan 11, 22)
  • COVID-19 pushed millions of Indians into poverty (The Economist, January 12,22)
  • Some experts predict a new COVID wave at the beginning of the summer (The Guardian, Jan 14, 22)
  • China’s zero COVID policy is creating problems for the manufacturing and distribution chain sectors (FT, Jan 16, 22)
  • Beijing reports the first case of the “ómicron” variant (The Guardian, Jan 15, 22)
  • COVID would have already left 17 million dead in the world (the official figures are 5.5 million), according to a study by the Barcelona Institute for Global Health, sponsored by the La Caixa Foundation (Diario Médico, Jan 15, 22)
  • The Epstein-Barr virus may play a role in the development of multiple sclerosis (NYT, Jan 13, 22)
  • The Economist looks at how healthcare is evolving into a consumer product (The Economist, Jan 15, 22)
  • Great boost to research on neurodegenerative diseases, with 260 drugs under development: Alzheimer’s, Amyotrophic Lateral Sclerosis (ALS), Huntington’s, multiple sclerosis, multiple systemic atrophy, Parkinson’s and others (Diariofarma, Jan 14, 22)

NATIONAL NEWS

  • Incidence of COVID and evolution of the sixth wave

o As of January 13, 2022, the 14-day cumulative incidence of COVID amounts to 2,923 cases/100,000 inhabitants. It is not clear if the peak of the wave has been reached or if we are still going up. In any case, the figures are very high (Official data Ministry of Health, update to  Jan 13, 22)

o Almost half of the Spanish provinces have ICUs at very high risk (El País, Jan 12, 22)

o The debate on those hospitalized “for” COVID and “with” COVID is introduced (El Independiente, Jan 10, 22)

  • “Influenzaization of the pandemic”

o An editorial in a journal of the SEMFYC (Spanish Society of Primary and Community Care Physicians), one of the three scientific societies of Primary Care, advocates the “influenza” approach  of the COVID, avoiding counting individual cases and omitting general measures of protection (AMF-SEMFYC, Towards the end of the exceptionality, Jan 10, 22)

o The other scientific societies of Primary Care, as well as most of the experts, took a stand against the previous proposal, at least until the sixth wave was passed.

o Notwithstanding the foregoing, both the President of the Government and Minister Darias, and certain representatives of the Community of Madrid, expressed their agreement with the approach as “influenza”

o Not only that, but that approach was taken to the WHO, which showed its disagreement. Spain wants to lead this debate in the EU (El Periódico de España, Jan 12, 22)

  • Regulation of the price of antigen tests

o The government (Interministerial Commission on the Price of Medicines) limits the price of antigen tests to 2.94 euros and they will continue to be sold only in pharmacies, with entry into force on Saturday, January 15, 2022. The price is 50% more expensive than in France and Germany (El País, Jan 13, 22)

o During the free sale period, the gross margin for pharmacies was 25-50% (El Economista, Jan 13, 22)

o FEFE expresses its “deep discomfort” at having to sell the tests at a loss (diariofarma, Jan 14, 22)

  • The third and fourth doses are extended

o The Ministry of Health announces a fourth dose for patients at risk and will extend the third to those over 18 years of age (La Razón, Jan 13, 22)

  • Purchase of COVID medications

o Spain closes an agreement with Pfizer to buy 344,000 doses of its drug against COVID

o The regions were unaware of this and ask for an equitable distribution (El Español, Jan 11, 22)

  • Serious problem with sick leave

o COVID causes more than 10,000 sick leaves per day in Spain (El Independiente, Jan 11, 22)

o This situation collapses health centers

o A system is put in place so that discharge and discharge (after 7 days) take place in the same act. Madrid calls for a regulatory change, to which the Government does not seem willing (El Economista Jan 12, 22)

  • Ayuso Plan to stimulate the birth rate in Madrid

o It is intended to go from 50,000 to 70,000 births/year in the region. The plan consists of aid of 500 euros, flexible working hours, deductions and support for assisted reproduction (La Razón, Jam 10, 22)

  • Other themes

o FACME disagrees with the recertification plan of the Ministry of Health, which launched a tender to hire a consultant (Official note from FACME,  Jan 13, 22)

o Teachers facing the return to classes, doubts with the new protocol and fears (El País, Jan 10, 22)

o A court condemns the Generalitat Valenciana to compensate the toilets for not giving them the means of protection (El País, Jan 11, 22)

o Ingesa attempts an agreement on biosimilars, which does not have the agreement of BIOSIM (diariofarma, Jan 9, 22)

COMPANIES, EMPLOYERS AND MAIN ACTORS IN HEALTH

  • A group of scientists in Texas announce a vaccine (CORBEVAX) that is cheaper, easier to make and patent-free (The Guardian, Jan 15, 22)
  • GSK rejects UNILEVER’s offer of 50,000 million pounds for its consumer division (FT, Jan 15, 22)
  • Medicare introduces major restrictions on the use of Biogen’s drug against Alzheimer’s (NYT, Jan 11, 22)
  • Adeslas will enter 1,655 million euros for MUFACE and ASISA 1,268 (PlantaDoce, Jan 12, 22)
  • Vivanta adjusts its network of centers, putting its beauty business up for sale (PlantaDoce, Jan 12, 22)
  • Pfizer says that it will have a new vaccine against “ómicron” ready in March (Redacción Médica, Jan 10, 22)
  • Merck acquires the US company EXELEAD for 789 million dollars (PlantaDoce, Jan 7, 22)
  • Medtronic reaches an agreement to acquire Affera (ConSalud, Jan 14, 22)
  • Eugin acquires the Delaware Institute of Reproductive Medicine (PlantaDoce, Jan 10, 22)
  • Caser Residencial acquires a new social health center in Laguna de Duero (PlantaDoce, Jan 13, 22)

Dental coverage in Medicare in the United States

 

 

 

See PDF of the article:

 

nejmp2115048

 

In a recent issue of N Engl J Med (December 2, 2021), the subject of Medicare dental coverage, currently excluded, and the many attempts to introduce it are discussed.

The article mentions that in 1958 the American Medical Association, the American Dental Association and other professional organizations created the Joint Council to Improve Health Care of the Aged, whose objective was to oppose the creation of what would later become Medicare (medical care public to those over 65 in the United States).

Despite that, Medicare was created in 1965, without dental care being covered. From this point of view we can say that the doctors lost, but the dentists won. Dental care continues to operate under a fee-for-service formula, with a high proportion of the cost of out-of-pocket money and with greater financial barriers than in other forms of health care.

After decades of attempts to cover dental care with Medicare, it appears that the American government is close to achieving this goal. There was a previous attempt in 2019 through a law passed in the House of Representatives, but rejected by the Senate. A law with similar claims was introduced in Congress in 2021, forming part of Joe Biden’s “reconciliation package.” The Centers for Medicaid and Medicare have already appointed a “chief dental officer.”

This time, the American Dental Association supports the introduction of dental care into Medicare, but only if it only covers people below 300% of the FPL (federal poverty level).

The health system in general is assuming the problems of the absence of dental coverage, in the form of millions of patients, including older adults, who present themselves in the emergency areas, hospitals and primary care for dental pain, a visit that generally concludes with the recommendation to go to a dentist, which many cannot afford. Untreated dental disease can lead to endocarditis, brain abscess, and mediastinitis.

Even if the law that includes dental care in Medicare is finally signed, many problems will remain to be solved, such as the need to enroll dental providers.

In any case, if this measure is finally introduced, it will have been a giant step in the improvement of American healthcare and, this time, with beneficial consequences for Europe and, specifically, for Spain, the country that dedicates the least public budget to dental care in European countries.

7 days in healthcare (November 29-December 5, 2021)

 

SUMMARY

From the international point of view, it is worth highlighting the beginning of the work of the WHO for the approval of a Treaty on pandemics. It seems that the alarm about the new “‘ ómicron “variant is lowered, after the WHO announcement that there had been no case of death. We must be attentive to the program of the new German coalition government, and its impact on the health system. It seems that its actions are concentrated in the pharmaceutical sector. The failure, for various reasons, of the COVAX platform for immunization of low- and middle-income countries is confirmed.

At the national level, the growth of COVID continues to figures that are already beginning to be worrying, despite the advantage over other European countries. The council of ministers approves the Mental Health Strategy, a plan that, unlike the one approved a few years ago on Primary Care, does have funding, despite having aroused reservations among experts. The council of ministers also approves the PERTE for health. As of December 13, the vaccines for children will be available.

Regarding companies, it should be noted that both Pfizer and Moderna are preparing to adapt their vaccines to the new COVID variant.

 

INTERNATIONAL

 

  • The WHO agrees on December 1, 2021 to begin negotiating an international agreement on how countries should prevent, prepare for and react to pandemics. The agreement is to hold a meeting before March 1, 2022 and discuss a draft before August 1, 2022 (British Medical Journal, Dec 2, 21)
  • A law to introduce dental care in Medicare is discussed in the American Congress (NEJM, 2 Dec 21)
  • An article is published that compares the evolution and behavior in 24 months of a large number of people from the Veterans Administration vaccinated with Moderna and Pfizer-BioNTech (NEJM, Dec 1 21)
  • The need for the health sector to contribute to decarbonization continues to be present (NEJM, Dec 2 21)
  • The WHO warns of a high risk due to the new “omicron” variant (FT Nov 29, 21)
  • WHO says there have been no deaths from the new “omicron” variant, despite its expansion (The Guardian, 4 Dec 21)
  • The “ómicron” variant, with a wide worldwide diffusion: apart from its origin in South Africa, and the expansion to 11 European countries, also present in Canada, Brazil, Australia and Saudi Arabia, among others (CNN Español, Dec 1 21)
  • Van der Leyden calls to discuss the mandatory nature of the vaccine (FT, Dec 1 21)
  • Analysts say that the economic impact of the “omicron” variant will not be important (FT, Nov 29, 21)
  • The program of the new German coalition government has an impact on the healthcare and pharmaceutical sector. Most important measures: price containment in medicines, push for healthcare digitization and use of medical data for research (Covington, Nov 29 21)
  • Biden rules out a new lockdown to tackle the new “omicron” variant (FT, Nov 29, 21)
  • The United Kingdom urgently calls a meeting of the G7 to discuss the problem of the new variant (La Razón, 28 Nov 21)
  • The new variant presents more than 50 mutations over the original from Wuhan (La Razón, Nov 29, 21)
  • COVAX has only distributed 26% of the promised covid vaccines for 2021. The most unanimous explanation is that rich countries have monopolized the market (El Español, Dec 4, 21)
  • The EMA would need three to four months to approve vaccines if they have to be modified by “omicron” (El Confidencial, Nov 30, 21)
  • Europe steps on the accelerator with the third doses in full uncertainty for the new variant (eldiario.es, Nov 29, 21)
  • The lack of vaccines, logistical limitations and the rejection of part of the population hinder immunization in Africa (El País, 28 Nov 21)
  • Germany imposes a de facto confinement to the unvaccinated: leisure and commerce will be banned (El País, 2 Dec 21)
  • Agreement between the Council and the European Parliament to strengthen the role of the ECDC (El Global, 30 Nov 21)

NATIONALS

 

  • COVID cases continue to rise, reaching an AI (cases per 100,000 in the last 14 days) of almost 250 (El Confidencial, Dec 3, 21)
  • Health advises limiting participants in social events during Christmas after the advance of COVID (La Razón 1 Dec 21)
  • The government does not have a “legal plan B” before the “omicron”, it trusts everything to vaccination and rejects restrictions that could affect the economy (La Razón, Dec 1 21)
  • The Government defends the need for an International Treaty on Pandemics, as stated by Minister Darias during the Extraordinary Assembly of the WHO in Geneva (ConSalud, 29 Nov 21)
  • The Council of Ministers approves the Mental Health Strategy 2022-2026, the last was of 2009. It is criticized by experts (Spanish Society of Psychiatry, Spanish Society of Dual Pathology) for its lack of ambition, although the effort of consensus. Among the criticisms is the lack of standards such as professional ratios, number of beds in children’s and adolescent hospitals, waiting lists, etc. It has financing of 100 million euros for the next three years, 30 million for 2022. Intervention in the workplace, the approach to suicide and the gender perspective, among the novelties of this Strategy (El Mundo, Dec 4, 21)
  • The council of ministers officially approves the PERTE for health. Investment of more than 1,400 million euros, between 2021 and 2023. These investment agendas are articulated through tenders, the creation of an investment, development and innovation (R + D + i) structure for advanced online therapies, launch of a public-private investment vehicle in advanced therapies (public-private commercial company) with the participation of companies with production capacity in Spain, elements of early coordination and identification of capacities and needs of the National Health System, public procurement innovative and pre-commercial, agreements with communities, private initiatives and co-programmed projects and public tenders (PlantaDoce, Nov 30 21)
  • The Interterritorial Council of December 2 addresses the Royal Decree of Specialties, so that it is approved before the end of 2021. It contemplates approving new specialties and reviewing access to specific training areas (ConSalud, Nov 30, 21)
  • Pfizer vaccines for children, available from December 13 (ConSalud, Dec 1 21)
  • AESEG presents a report “The sector of generic drugs in the economic and social reconstruction of Spain”, in which it advocates a differential price of generics in relation to brands (AESEG, Dec 1 21)

COMPANIES, EMPLOYERS AND MAIN ACTORS IN HEALTH

 

  • Continuity of care, interoperability, innovation and the promotion of the SDGs (Sustainable Development Goals), among the objectives of the IDIS Foundation for 2022 (ConSalud, 2 Dec 21)
  • Teladoc Health grows 81% in the third quarter (PlantaDoce, Dec 1 21)
  • Pfizer and Moderna are preparing to adapt their vaccines to the new “omicron” variant (El Global, Nov 29, 29)
  • Merck’s COVID Treatment (Molnupiravir), Endorsed by FDA (NYT, Nov 30 21)
  • HM Hospitales will have a new space of 1,000 square meters in Valdedebas (PlantaDoce, Nov 30, 21)
  • HIPRA relies on its covid vaccine to grow 13% in 2021 (PlantaDoce, Dec 1 21)
  • The major private equity companies (CVC, Advent, Cinven, PAI, KKR,…) prepare offers for around 1,500 million for IVI (CincoDías, Nov 30, 21)